Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Imugene Limited (AU:IMU)
ASX:IMU
Imugene Limited (IMU) Share Price & Analysis
36 Followers
IMU Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.04 - AU$0.15
Previous CloseAU$0.08
Volume2.73M
Average Volume (3M)15.87M
Market Cap
AU$600.07M
Enterprise ValueAU$479.05M
Total Cash (Recent Filing)AU$99.89M
Total Debt (Recent Filing)AU$673.43K
Price to Earnings (P/E)-6.0
Beta1.74
Next Earnings
Aug 30, 2024EPS Estimate
-AU$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares OutstandingN/A
10 Day Avg. Volume34,707,258
30 Day Avg. Volume15,867,322
Standard Deviation0.29
R-Squared0.13
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.15Price Target Upside85.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Imugene Limited News
PremiumCompany Announcements
Imugene Director’s Shareholding Adjustment
PremiumCompany Announcements
Imugene Limited Issues New Equity Securities
PremiumCompany Announcements
Imugene Limited Announces Investor Webinar
PremiumCompany Announcements
Imugene Partners with Kincell for Growth and Savings
PremiumCompany Announcements
Imugene Limited Announces Securities Cessation
PremiumCompany Announcements
Imugene Limited Issues New Employee Incentives
PremiumCompany Announcements
Imugene Advances Promising Cancer Therapy TrialPremiumCompany Announcements
Imugene’s Breakthroughs Offer Cancer Treatment HopeOptions Prices
Currently, No data available
---
Ownership Overview
9.72% Insiders
2.70% Mutual Funds
2.93% Other Institutional Investors
84.65% Public Companies and
Individual Investors
IMU FAQ
What was Imugene Limited’s price range in the past 12 months?
Imugene Limited lowest share price was AU$0.04 and its highest was AU$0.15 in the past 12 months.
What is Imugene Limited’s market cap?
Currently, no data Available
When is Imugene Limited’s upcoming earnings report date?
Imugene Limited’s upcoming earnings report date is Aug 30, 2024 which is in 118 days.
How were Imugene Limited’s earnings last quarter?
Imugene Limited released its earnings results on Feb 28, 2024. The company reported -AU$0.01 earnings per share for the quarter, missing the consensus estimate of AU$0 by -AU$0.01.
Is Imugene Limited overvalued?
According to Wall Street analysts Imugene Limited’s price is currently Undervalued.
Does Imugene Limited pay dividends?
Imugene Limited does not currently pay dividends.
What is Imugene Limited’s EPS estimate?
Imugene Limited’s EPS estimate is -AU$0.01.
How many shares outstanding does Imugene Limited have?
Imugene Limited has 7,319,811,000 shares outstanding.
What happened to Imugene Limited’s price movement after its last earnings report?
Imugene Limited reported an EPS of -AU$0.01 in its last earnings report, missing expectations of AU$0. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Imugene Limited?
Currently, no hedge funds are holding shares in AU:IMU
---
Imugene Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.15 (85.62% Upside)
AU$0.15 (85.62% Upside)
Blogger Sentiment
Bullish
AU:IMU Sentiment 92%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $718.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-40.00%
12-Months-Change
Fundamentals
Return on Equity
-42.91%
Trailing 12-Months
Asset Growth
9.08%
Trailing 12-Months
Company Description
Imugene Limited
Imugene Ltd specializes is a clinical-stage immuno-oncology company. Its product includes HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being Research, Development, and Commercialisation of oncolytic immunotherapies.
---
IMU Stock 12 Months Forecast
Average Price Target
AU$0.15
▲(85.62% Upside)
Technical Analysis
Best Analysts Covering IMU
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
-33.43%
reiterated a buy rating 12 days ago
Copying John Hester's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -33.43% per trade.
---